Carboplatin Dose Calculator (Calvert Formula)

What Is the Carboplatin Dose Calculator?

The carboplatin dose calculator applies the Calvert formula to compute the precise milligram dose of carboplatin chemotherapy tailored to each patient's kidney function. Unlike most cytotoxic agents dosed by body surface area, carboplatin is eliminated almost entirely through glomerular filtration, which means renal function directly governs systemic drug exposure. The Calvert formula, first published in the British Journal of Cancer in 1989 and subsequently adopted by major oncology guidelines worldwide, remains the gold standard for carboplatin dosing. This carboplatin calculator automates both the Cockcroft-Gault creatinine clearance estimation and the final Calvert dose computation, reducing arithmetic error at the point of care.

The Calvert Formula

The core equation is: Dose (mg) = AUC × (GFR + 25)

• AUC (Target Area Under the Curve) — Expressed in mg·min/mL, this value represents the desired systemic carboplatin exposure per cycle. Typical targets: AUC 5–6 for first-line combination therapy, AUC 4 for pretreated patients in combination regimens, and AUC 7 for single-agent use. The treating oncologist selects the AUC based on tumor type, prior platinum exposure, and patient performance status.
• GFR (Glomerular Filtration Rate, mL/min) — Represents the kidneys' filtration capacity. In clinical practice, estimated creatinine clearance (CrCl) from the Cockcroft-Gault equation substitutes for measured GFR when isotope studies are unavailable.
• 25 (Non-renal clearance constant, mL/min) — Derived from original pharmacokinetic studies by Calvert et al., this constant accounts for carboplatin eliminated through non-renal pathways including protein binding and spontaneous hydrolysis.

Estimating GFR: The Cockcroft-Gault Equation

The Cockcroft-Gault (CG) formula estimates creatinine clearance as a surrogate for GFR: CrCl = [(140 − age) × weight] / (72 × SCr) × 0.85 (if female)

• Age (years) — Renal function declines progressively with age, so older patients receive a lower CrCl estimate and a proportionally lower carboplatin dose for the same AUC target. A 70-year-old will have meaningfully lower estimated GFR than a 45-year-old with identical creatinine.
• Weight (kg) — Actual body weight is standard for most patients. For patients with BMI > 30, adjusted body weight (IBW + 0.4 × [ABW − IBW]) is recommended to prevent overestimation of creatinine clearance and resultant overdose.
• Serum Creatinine / SCr (mg/dL) — Normal adult range is 0.6–1.3 mg/dL. Lower creatinine values yield higher CrCl estimates and larger calculated doses; clinicians should verify whether the reporting laboratory uses IDMS-standardized or Jaffe-method assays, as this directly affects dosing safety.
• Sex correction factor (0.85 for female patients) — Women generally carry less skeletal muscle mass relative to body weight, producing less creatinine per kilogram. The 0.85 multiplier corrects for this physiological difference in the CG equation.

FDA and NCI GFR Cap at 125 mL/min

Following widespread laboratory adoption of IDMS-standardized creatinine assays, the National Cancer Institute issued formal dosing guidance in October 2010 recommending that estimated GFR be capped at 125 mL/min. IDMS-calibrated assays produce serum creatinine values approximately 10–20% lower than older Jaffe-method assays. Without the cap, these lower values generate unrealistically high GFR estimates, inflating the calculated carboplatin dose and substantially increasing risk of severe thrombocytopenia — the dose-limiting toxicity of carboplatin. The cap is now standard practice in most oncology centers and is applied by default in this calculator.

Worked Clinical Example

A 58-year-old female patient weighs 68 kg and has a serum creatinine of 0.9 mg/dL. Target AUC is 5 (first-line ovarian cancer regimen, carboplatin plus paclitaxel).

1. Estimate CrCl: [(140 − 58) × 68] / (72 × 0.9) × 0.85 = [82 × 68] / 64.8 × 0.85 = 5,576 / 64.8 × 0.85 ≈ 73.1 mL/min
2. Apply GFR cap: 73.1 mL/min is below 125 mL/min — no cap applied.
3. Calculate dose: 5 × (73.1 + 25) = 5 × 98.1 = 490.5 mg (rounded to 490 mg per institutional protocol).

Clinical Use Cases

The carboplatin calculator applies across a wide range of platinum-sensitive malignancies:

• Ovarian and fallopian tube cancer — First-line carboplatin plus paclitaxel targets AUC 5–6, as established in the GOG-158 and ICON4 landmark trials.
• Non-small cell and small cell lung cancer (NSCLC/SCLC) — A 2022 analysis published via PMC/NIH confirmed that Calvert-based AUC dosing reduces both underdosing and nephrotoxicity risk compared to BSA-based approaches in lung cancer patients.
• Head and neck, bladder, and endometrial cancers — AUC targets typically range from 4 to 6 depending on regimen, performance status, and prior treatment burden.
• High-dose conditioning for autologous stem cell transplant — AUC 7 is used in select conditioning protocols, requiring especially careful renal monitoring.

Sources and Validation

This calculator's methodology follows the original Calvert formula (Calvert et al., British Journal of Cancer, 1989) and the NCI AUC-Based Dosing Memo (October 2010). These authoritative references define the formula parameters, the Cockcroft-Gault GFR substitution, and the IDMS cap that underpin all calculations. Always verify final doses with a licensed oncology pharmacist or physician before drug preparation and administration.